Pulling SEC filings + quote and writing the call…

Larimar Therapeutics, Inc.
Next earnings Aug 12, 2026 (after close) · consensus $-0.39 EPS
Last earnings -5.1% on 2026-05-14
Conservative balance sheet (liabilities/equity 0.87x).
Larimar Therapeutics, Inc. shows $0.00 in FY2019 revenue, and -212.2% ROE.
Sources: SEC EDGAR (CIK 0001374690, latest 10-Q filed 2026-05-14) · EODHD · as of 6/22/2026, 9:52:08 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.
The risks, catalysts, 12-month price target and the cited SEC figures behind this rating — with Pro.
Unlock with Pro€15/mo · cancel anytime
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$50.5M | -$36.5M | -$41.8M | -$90.9M | -$172M |
| Net income | -$50.6M | -$35.4M | -$36.9M | -$80.6M | -$166M |
| Diluted EPS | -$2.95 | -$1.37 | -$0.84 | -$1.32 | — |
| Net margin | — | — | — | — | — |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
1483 tracked peers · median
| 2026-02-27 | Flynn James E Director | Buy | 1.08M @ $5.00 | $5.42M |
| 2026-02-27 | Flynn James E Director | Buy | 1.08M @ $5.00 | $5.42M |
| 2026-02-27 | Flynn James E Director | Buy | 832K @ $5.00 | $4.16M |
| 2026-02-27 | Flynn James E Director | Buy | 2.00M @ $5.00 | $10.0M |
| 2026-02-27 | Hamilton Thomas Edward Director | Buy | 100K @ $5.00 | $500K |
Recent news tone vs the market's typical (which skews positive). A soft signal, not a recommendation.
Dates from 8-K (Item 2.02); beat/miss = reported EPS vs consensus (Finnhub, recent quarters); move = prior close → close on/after.